{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:40:01Z","timestamp":1756287601145,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2015,12,21]]},"abstract":"<jats:p>Chronic myeloid leucaemia (CML) is a chronic myeloproliferative disorder characterised by a reciprocal translocation between the chromosomes 9 and 22 resulting in constitutionally active tyrosine kinase signalling. BCR-ABL tyrosine kinase inhibitors (TKIs) are highly effective molecules in the treatment of CML. Unfortunately, these novel therapeutic agents are accompanied by various side effects, and haematological, cutaneous and metabolic abnormalities are among the most prevalent. Nilotinib, a second-generation TKI, has been shown to cause both\u2014cutaneous lesions and lipid profile abnormalities. We present two CML cases developing xanthelasma palpebrarum while receiving nilotinib. Case 1 also acquired a lipid abnormality following the start of nilotinib therapy, while case 2 meanwhile stayed normolipidemic. In addition to a low cholesterol diet, atorvastatin was prescribed to case 1. Currently, both cases are normolipidemic and continuing their nilotinib therapy. Xanthelasma palpebrarum secondary to nilotinib therapy is new to the literature.<\/jats:p>","DOI":"10.1136\/bcr-2015-213511","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T08:53:10Z","timestamp":1452588790000},"page":"bcr2015213511","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Xanthelasma palpebrarum: a new side effect of nilotinib"],"prefix":"10.1136","volume":"2016","author":[{"given":"Irmak","family":"Sayin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ufuk University Medical Faculty, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meltem","family":"Ayli","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ufuk University Medical Faculty, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Kemal","family":"O\u011fuz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ufuk University Medical Faculty, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcldane","family":"Cengiz Seval","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ufuk University Medical Faculty, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,1,12]]},"reference":[{"unstructured":"Abernethy AP , McCrory DC . Report on the relative efficacy of oral cancer therapy for medicare beneficiaries versus currently covered therapy: part 3, Imatinib for Chronic Myeloid Leukemia (CML) [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US), 2005. AHRQ Technology Assessments.","key":"2025082702142361000_2016.jan12_1.bcr2015213511.1"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.2","DOI":"10.1053\/j.seminhematol.2009.01.011"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.3","DOI":"10.1111\/jdv.12172"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.4","DOI":"10.3324\/haematol.2014.104075"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.5","DOI":"10.1056\/NEJMoa022457"},{"key":"2025082702142361000_2016.jan12_1.bcr2015213511.6","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1200\/jco.2007.25.18_suppl.7004","article-title":"Dasatinib 50mg or 70mg BID compared to 100mg or 140mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.7","DOI":"10.1056\/NEJMc053425"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.8","DOI":"10.1056\/NEJMoa055104"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.9","DOI":"10.1182\/blood-2007-03-080689"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.10","DOI":"10.1200\/JCO.2009.25.9937"},{"unstructured":"Durrington P , Sniderman A, eds . Hyperlipidaemia. Oxford, Health Press, 2000.","key":"2025082702142361000_2016.jan12_1.bcr2015213511.11"},{"unstructured":"Thompson GR, ed . A handbook of hyperlipidemia. London: Current Science, 1990.","key":"2025082702142361000_2016.jan12_1.bcr2015213511.12"},{"doi-asserted-by":"publisher","key":"2025082702142361000_2016.jan12_1.bcr2015213511.13","DOI":"10.5999\/aps.2012.39.4.435"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-213511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:14:37Z","timestamp":1756286077000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-213511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":13,"alternative-id":["10.1136\/bcr-2015-213511"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-213511","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,1,12]]}}}